Leo Pharma to acquire dermatology products from Bayer

LEO Pharma has entered into a definitive agreement to buy Bayer�s global prescription dermatology unit. The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections and rosacea, and a range of topical steroids with an annual turnover in 2017 of more than 280 million euros. It will enable LEO Pharma to expand significantly in key markets worldwide and broaden its therapeutic areas. Bayer�s global medical dermatology portfolio, which includes prescription treatment solutions for acne (Skinoren�), fungal skin infections (Travogen and Travocort) and rosacea (Finaea), and a range of topical steroids (Advantan, Nerisona, and Desonate), will add complementary treatment areas and strengthen the existing business of LEO Pharma worldwide, allowing the company to more than double sales in some markets. The transaction does not include Bayer�s over-the-counter dermatology portfolio of brands such as Bepanthe� and Canestenamongst others.